Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic agreement with the ADAP Crisis...
Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline
Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) and Kartos Therapeutics announced a definitive merger agreement under...
Biocytogen Prevails in Shanghai IP Court as Harbour BioMed Patent Infringement Claims Dismissed – RenNano Platform Cleared of Antibody Technology Violations
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced it has received a favorable...
Innovative Medical Management Subsidiary Cereblink Secures Registration for AM5 Upper Limb Rehabilitation Exoskeleton – EMG-Driven System Targets CNS Injury Recovery
Innovative Medical Management Co., Ltd. (SHE: 002173) announced that its holding subsidiary Cereblink (Hangzhou) Technology...
Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories
Hua Medicine (HKG: 2552) announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative...
AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
AbbVie (NYSE: ABBV) announced on June 26, 2026, that the U.S. Food and Drug Administration...
Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval
Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed...
Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use
Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines...
Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of...
J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for...
China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs
China’s Center for Drug Evaluation (CDE) has released the 108th batch of reference preparations for...
NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate
China’s National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National...
Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China’s National Medical Products Administration (NMPA)...
Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
The Department of Health – Abu Dhabi (DoH) has signed a memorandum of understanding (MoU)...
Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization...
Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon Canada announced the official commercial launch of...
AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...
YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders
Shenzhen YHLO Biotech Co., Ltd. and Beijing Jingyi Bio have formally signed a comprehensive cooperation...
Sanofi’s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets
Sanofi S.A. (NASDAQ: SNY) announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved...